The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

NOVEMBER 15, 2024

The first subject has been dosed in the Phase III trial of the InnoCare Pharma’s novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for the treatment of atopic dermatitis (AD) in China. Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world.

Dermatitis 36

Dermatitis Safety Marketing Dermatology 36

The Dermatology Digest

JULY 27, 2023

So we just don’t have the standardization of what is being eliminated and no consensus as to what should be eliminated based on safety studies. There’s plenty of natural things that can cause irritant contact dermatitis. We have lots of experience and long-term safety with petrolatum.

Sustainability 36

Sustainability Skincare Safety Ingredients 36

Kind of Stephen

AUGUST 3, 2022

It’s marketed as a soothing ingredient and sometimes, often illegally, as a disinfectant, anti-inflammatory, acne treatment, or something that can “trigger an immune boost…repair and heal skin”. Information from experiments about bleach baths is likely what was warped and inflated into the marketing of skincare sprays with hypochlorous acid.

Sanitation and Sterilization 52

Sanitation and Sterilization Sanitation Eczema Skincare 52

The Dermatology Digest

DECEMBER 20, 2023

Before Harbor Health, he led product and go-to-market functions for CVS’s kidney care and home business units. The company is also conducting a 250-patient phase 2b trial of its topical JAK 1/3 inhibitor, called ATI-1777 in atopic dermatitis. Mr. Raducha-Grace recently served as Head of Clinical Partnerships at Harbor Health.

Dermatology 36

Dermatology Surgery Eczema Office 36

Aesthetics Advisor

AUGUST 6, 2023

Spreading throughout the American South, pellagra patients suffered severe symptoms known as the "4 D's": dermatitis, diarrhea, dementia, and death. Amongst them, Niagen® is the only patented form that has gone through the regulatory procedures to assess safety in key markets around the world.

Rosacea 36

Rosacea Dermatitis Diet Safety 36

The Beauty Brains

OCTOBER 17, 2016

According to Fisher’s Contact Dermatitis, acne can result from topical application of cosmetic products via two mechanisms. In most cases, when a company tells you their shampoo or conditioner is “more concentrated” it’s probably just a marketing gimmick. But there are plenty of cheaper peptide products on the market.

Sun Protection 40

Sun Protection Extractions Ingredients Comedogenic 40

Aesthetics Advisor

JUNE 16, 2024

But the authors also noted that “further studies are needed to assess the long-term efficacy and safety of this technique.” Says Dr. Hartman, the lack of safety data and FDA approval are what make exosomes in serums and creams such a contentious trend. freeze) them. Hartman refers to exosomes as "the AI of skin care."

Aromatherapy 36

Aromatherapy Injections Ingredients Moisturization 36

The Dermatology Digest

DECEMBER 13, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended granting marketing authorization for nemolizumab (Nemluvio. Galderma) for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU).

Dermatitis 36

Dermatitis Safety Marketing Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

AUGUST 13, 2024

The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis. Nemolizumab was generally well tolerated, and its safety profile was consistent with the phase II trial, and between the OLYMPIA 1 and 2 trials.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

NOVEMBER 29, 2024

Nemolizumab was well-tolerated, and its safety profile was generally consistent with previous studies. The full results from the Phase 3 OLYMPIA 1 trial were published in JAMA Dermatology. Based on data from the OLYMPIA clinical trial program, nemolizumab has been approved by the U.S.

Clinic 36

Clinic Dermatitis Safety Dermatology 36

The Dermatology Digest

FEBRUARY 9, 2024

Fully 70% of individuals who live with severe CHE admit to problems in performing everyday activities and suffering disruption in their daily life due to the condition , according to a study in contact dermatitis.” TDD: Why is it so significant that the DELTA FORCE Trial was head-to-head?

Eczema 36

Eczema Dermatitis Marketing Safety 36